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Introduction: Nailfold videocapillaroscopy (NVC) in systemic sclerosis (SSc) is a procedure commonly used for
patient classification and subsetting, but not to define disease activity (DA). This study aimed to evaluate whether
the number of micro-haemorrhages (MHE), micro-thrombosis (MT), giant capillaries (GC), and normal/dilated
capillaries (Cs) in NVC could predict DA in SSc.
Methods: Eight-finger NVC was performed in 107 patients with SSc, and the total number of MHE/MT, GC, and the
mean number of Cs were counted and defined as number of micro-haemorrhages (NEMO), GC and Cs scores,
respectively. The European Scleroderma Study Group (ESSG) index constituted the gold standard for DA assessment,
and scores ≥3.5 and =3 were considered indicative of high and moderate activity, respectively.
Results: NEMO and GC scores were positively correlated with ESSG index (R = 0.65, P <0.0001, and R = 0.47, P <0.0001,
respectively), whilst Cs score showed a negative correlation with that DA index (R = −0.30, P <0.001). The area under
the curve (AUC) of receiver operating characteristic plots, obtained by NEMO score sensitivity and specificity values in
classifying patients with ESSG index ≥3.5, was significantly higher than the corresponding AUC derived from either
GC or Cs scores (P <0.03 and P <0.0006, respectively). A modified score, defined by the presence of a given number
of MHE/MT and GC, had a good performance in classifying active patients (ESSG index ≥3, sensitivity 95.1%, specificity
84.8%, accuracy 88.7%).
Conclusions: MHE/MT and GC appear to be good indicators of DA in SSc, and enhances the role of NVC as an easy
technique to identify active patients.Introduction
Systemic sclerosis (SSc) is a connective tissue disease clin-
ically characterized by Raynaud’s phenomenon, and pro-
gressive fibrotic changes in the skin and internal organs,
such as heart, lung, and kidney. Subsets of SSc have been
defined, that is, limited cutaneous (lc) SSc, diffuse cutane-
ous (dc) SSc and SSc without skin involvement [1].
As in other systemic autoimmune diseases, SSc has a
clinical course characterized usually by early phases of* Correspondence: d.sambataro@hotmail.it
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article, unless otherwise stated.activity. A small vessel vasculopathy, characterised by
peripheral vascular and interstitial mononuclear cell in-
filtration, represents the hallmark of the disease in the
early phase. Conversely, in the late disease stages, the en-
tire process may evolve to irreversible fibrotic changes of
the involved tissues and organs [2-4]. This should induce
the clinician to define an early diagnosis and recognize
any active phase of the disease, in order to contrast the ir-
reversible final damage by introducing an appropriate
treatment [5-7].
The assessment of disease activity (DA) in SSc is a ra-
ther difficult challenge, and only a composite index thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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items has, so far, been proposed and validated [8,9].
Nailfold videocapillaroscopy (NVC) is a simple method
that allows the clinician to observe and follow up the
disease-related micro-vascular changes in an easily access-
ible capillary bed [10]. NVC plays an important role in the
diagnosis of SSc and is included as an item even in the
2013 classification criteria for SSc [11]. In addition, differ-
ent NVC patterns have been defined and their prognostic
value underlined [12-14]. Finally, NVC has been used to
define the different phases of the disease. This allows
distinguishing patients with early, active, and late NVC
pattern, where the active pattern is defined by the pres-
ence of numerous ectasic and giant capillaries (GC),
ramified capillaries, micro-haemorrhages (MHE) and
micro-thrombosis (MT), and initial loss of capillaries
with avascular areas [15].
In the present study, we reconsider the specific NVC
abnormalities that have been suggested to be increased
(MHE, MT, and GC), or progressively reduced (number
of capillaries, Cs) during the active phases of disease, to
verify whether some quantitative combination of these
features could be useful to identify patients with a rele-
vant level of DA.
We decided to assess the presence of MT together
with that of MHE separately from that of GC.
This statement was based on the present interpretation
of micro-vascular NVC abnormalities in SSc. It has been
suggested that MT and MHE are strictly related to each
other, and represent the final evolution of enlarged capil-
lary loops in a rapidly progressive pathological process
[16]. Conversely, GC formation is certainly the first re-
sponse to micro-vascular aggression and damage [17], but
they may remain substantially unchanged when repeatedly
observed in NVC in a slowly evolving or stable disease
[18]. Consequently, the progressive reduction of the num-
bers of Cs can be regarded as the final result of capillary
bed pathological aggression, and also of the substantial
failure of capillary reconstruction attempts [17,18].
Methods
Patients
One hundred and seven patients who met the American
College of Rheumatology/European League Against
Rheumatism (ACR/EULAR) classification criteria for
SSc [11] formed the study population. They were also
classified as having lcSSc or dcSSc following the LeRoy
criteria [1]. Current pregnancy, diabetes, smoking and
onicophagic habitus, presence of anti-phospholipid anti-
bodies, and assumption of beta blockers, all conditions
that may influence the NVC pattern, were considered as
exclusion criteria from the study. At the moment of
study enrolment, 49 out of the 107 patients were treated
with infusion of intravenous prostanoids (42 with monthlyiloprost and 7 with weekly alprostadil), and 8 were taking
bosentan. Furthermore, all of the enrolled patients were
under treatment with low-dose acetylsalicylic acid.
Nailfold videocapillaroscopy
The nailfold capillaries of all fingers of both hands, ex-
cluding thumbs, were examined in each patient using
a videocapillaroscope with a 200× magnification lens.
Four consecutive 1-mm fields for a total extension of
4 mm in the middle of nailfold were examined. The de-
rived digital images were then stored and analysed by
using dedicated software (Videocap Scalar Co. Ltd, DS
MediGroup, Milan, Italy).
In Figure 1 some typical examples of what we have con-
sidered as capillaroscopic MHE and MTare shown [19].
The cumulative number of MHE and MT observed in
the images obtained from eight fingers in each patient
was calculated, and defined as the NEMO score (number
of micro-haemorrhages). Each separate MHE and MT
was counted as one in this score, independently of its
size. Similarly, the total number of GC, defined as capil-
laries with a diameter over 50 μm [17], and the mean
number of normal or slightly dilated Cs observed in the
same NVC fields, were also counted in each patient, and
defined as the GC and Cs scores, respectively.
The NVC images were used to subclassify patients in
different disease stages, according to a previously pro-
posed method [15] that indicated three different capil-
laroscopic patterns: (i) ‘early pattern’, classified as initial
stage of disease, characterized by the presence of few GC
and capillary MHE, no evident loss of Cs and relatively
well-preserved capillary distribution; (ii) ‘active pattern’,
classified as the acclaimed stage of disease, characterized
by numerous GC and capillary MHE, moderate capillary
loss and mildly disorganized capillary architecture; and
(iii) ‘late pattern’, as advanced disease, with few or absence
of GC and MHE, extensive capillary loss, and severe
disorganization of the normal capillary architecture.
Clinical work-up and assessment of disease activity
The European Scleroderma Study Group (ESSG) index
was taken as the gold standard for DA assessment [8,9].
This a composite scoring system that includes a number
of clinical, instrumental, and serological items, derived
by a multivariate analysis performed in a cohort of pa-
tients with both lcSSc and dcSSc [8]. A second study
carried out in a completely different cohort of patients
allowed to finally demonstrate that this scale was a reli-
able and a valid method to assess DA in SSc [9]. Follow-
ing the ESSG indications, a score ≥3.5 was considered
to have a good sensitivity and specificity in separating
patients with high DA level. In addition, we also took
into account a cut-off value of 3.0 [20] in order to also in-
clude patients with moderate level of DA. A clinical work-
Figure 1 Example of haemosiderin deposits taken into account when calculating the NEMO score. (A) Two micro-haemorrhages of
relevant size are evident in the cuticle border, as a result of erythrocyte extravasation following the rupture of capillaries. The consequent
haemosiderin deposits assume a round form; (B) numerous synchronous micro-haemorrhages are observed aligned in the distal row of the
cuticle. Synchronicity of events is defined by the presence of haemosiderin deposits in the distal row of capillaries aligned at the same level [16];
(C) a haemosiderin deposit that mirrors the shape of a capillary loop is shown. This aspect is considered indicative of a micro-thrombosis [19].
NEMO, number of micro-haemorrhages.
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within the month of NVC performance.
The modified Rodnan skin sScore (mRSS), that is, an
important item also included in the ESSG activity index,
was performed by experienced physicians (NDP, WM, EZ)
other than those who performed NVC (DS, GS). This score
is the most widely used method to assess the skin thicken-
ing by the exploration of 17 different body sites. The clin-
ician scores skin thickness on a scale ranging from 0 to 3.
The mRSS has showed to be a valid method to assess
skin involvement in SSc, closely related to the skin
histological features, and to have a good inter-observer
reliability [21-23].Statistical analysis
Statistical analysis was performed by standard procedures
using IBM SPSS™ Statistics 21 (IBM, Armonk, NY, USA)
and GraphPad Prism™ 6 software package (GraphPad
Software Inc., La Jolla, CA, USA).
Since NEMO, GC and Cs scores did not appear to have
a normal distribution, we used non-parametric tests to
compare these variables with other categorical or ordinal
variables taken into account in the study.
A logistic regression model was also tested to assess
the contribution of defined values of NEMO, GC and Cs
scores in predicting the presence of different level of DA
according to predefined ESSG cut-off values.
Receiver operating characteristic (ROC) curves were
constructed by plotting sensitivity and specificity values of
NEMO, GC and Cs scores in correctly classifying patients
having or not having an active disease phase. The Hanley-
McNeil test was applied to test the significance of the
differences between the areas under the ROC curves ob-
tained from the analysed NVC variables.
Weighted Cohen’s k statistics were preliminarily applied
to evaluate the interobserver agreement in both counting
NVC abnormalities and assessing mRSS, and resulted to
be good in both cases (0.69 and 0.75, respectively).No correction of the statistical results was made for
the presence of missing values, since no data were missed
in our database.
Ethical rules
This study was conducted according to the Helsinki
Declaration and approved by the ethics committee of
‘Ospedale G. Pini, Milan, Italy’, where the study was car-
ried out and all the study patients were recruited. A
written informed consent was obtained from all of the
enrolled patients.
Results
The patients with SSc had a mean age of 55.8 yrs. (range
18 to 84 yrs.) and mean disease duration of 6.1 yrs.
(range 0 to 30 yrs.). As expected, females represented
the large majority of the study population (97/107). The
main demographic, clinical and laboratory data of the
patients are summarised in Table 1.
In accordance with the ESSG index pre-defined cut-off
value suggested to distinguish patients with high level of
DA, that is, an ESSG index ≥3.5, 32 out of the 107 pa-
tients could be considered as very active (14 with dcSSc
and 18 with lcSSc). Conversely, active patients became
41 when an ESSG index ≥3.0 was used as cut-off value to
also included patients with moderate DA (26 with lcSSc
and 15 with dcSSc). The main clinical characteristics of
nine additional active patients were reported in Table 2. It
appears evident that all of these patients showed relevant
aspects suggesting a phase of DA.
The NEMO score appeared to be a good predictor for
DA since NEMO values were strictly correlated with both
ESSG index scores (Spearman’s R =0.65, P <0.0001), and
with mRSS (R =0.59, P <0.001), but not with patients’ age
and disease duration. When the other components of
ESSG activity index were considered, NEMO score ap-
peared to be significantly higher in patients presenting
with scleredema (Mann-Whitney U Z value =4.59,
P <0.0001), worsening of skin (Z =5.79, P <0.0001),
Table 1 Demographic, clinical, and serological features, according to ESSG index [8,9]
Whole cohort Patients with lcSSc Patients with dcSSc
Patients (F/M) 107 (97 F, 10 M) 57 (53 F, 4 M) 50 (44 F, 6 M)
Mean age (range) (yrs.)1 55.8 (18-84) 58.1 (28-84) 53.3 (18-84)
Mean disease duration (range) (yrs.) 6.1 (0.5-30) 7.4 (0.5-30) 4.8 (0.5-20)
ESSG index ≥3.5 (no. of pts.)2 (%) 32 (29.9%) 18 (16.8%) 14 (13.1%)
Mean mRSS (range) (yrs.) 3.1 (0-32) 2.4 (0-5) 3.5 (0-32)
Scleredema (no. of pts.) (%) 60 (56.1%) 32 (56.1%) 28 (56.0%)
Δ3 Skin involvement (no. of pts.) (%) 18 (16.8%) 11 (19.2%) 7 (14.0%)
Ulcers (no. of pts.) (%) 22 (21.5%) 11 (19.2%) 11 (22.0%)
Δ1 Vascular features (no. of pts.) (%) 25 (23.4%) 14 (24.5%) 11 (22%)
Arthritis (no. of pts.) (%) 5 (4.7%) 3 (5.2%) 2 (4%)
DLCO <80%4 (no. of pts.) (%) 67 (63.2%) 35 (61.4%) 32 (64.0%)
Δ1 Cardiopulmonary features (no. of pts.) (%) 20 (18.7%) 10 (17.5%) 10 (20.0%)
ESR >30 mm/h (no. of pts.) (%) 32 (29.9%) 14 (24.5%) 18 (36.0%)
Hypocomplementemia (no. of pts.) (%) 12 (11.7%) 9 (15.7%) 3 (6.0%)
1Yrs. = years; 2pts = patients; 3worsening in the specific organ/system involvement; 4a diffusing lung capacity for carbon monoxide below 80% of predicted value.
ESSG, European Scleroderma Study Group; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; mRSS, modified Rodnan skin
score; DLCO, diffusing capacity; ESR, erythrocyte sedimentation rate.
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features (Z =3.18, P <0.002), current digital ulcers (Z = 2.91,
P <0.005), and erythrocyte sedimentation rate (ESR) over
30 mm/h (Z = 3.79, P <0.0001).
Similarly, also the GC score was significantly corre-
lated with ESSG index score and with mRSS (R = 0.47,
P <0.0001, and R = 0.34, P <0.001, respectively). Among
the different components of ESSG scoring system, GC
score was significantly associated with the presence of
scleredema (Z = 4.8, P <0.0001), digital ulcers (Z = 2.80,Table 2 Disease activity assessment of nine patients with ESS
Patient code 15 37 43
mRSS 0 2 4
Scleredema - + +
Δ1 Skin features - - -
Ulcers - - +
Δ1 Vascular features - - -
Arthritis + - -
DLCO <80%2 + + +
Δ1 Cardiopulmonary features + + -
ESR >30 mm/h3 + + -
Hypocomplementemia - - -
NVC pattern Active Active Active
NEMO score 7 12 3
GC score 9 3 7
Cs score 7 8 7
1Worsening in the specific involvement; 2a diffusing lung capacity for carbon mono
30 mm/h. ESSG, European Scleroderma Study Group; mRSS, modified Rodnan skin s
nailfold videocapillaroscopy; NEMO, number of micro-haemorrhages; GC, giant capiP <0.01) and worsening of cutaneous (Z = 3.72,
P <0.0005), vascular (Z = 2.64, P <0.01), and cardio-
pulmonary (Z = 2.12, P <0.05) features.
As expected, negative correlations were found between
Cs score and both ESSG index and mRSS (R = −0.27,
P = 0.004, and R = −0.26, P = 0.007). Furthermore, Cs
score was significantly lower in patients with scleredema
(Z = −3.02, P = 0.003), digital ulcers (Z = −3.08, P = 0.002),
and diffusing capacity (DLCO) <80% of predicted value
(Z = −3.4, P = 0.001).G score = 3
53 65 69 89 90 93
5 8 4 6 6 0
+ + + + + +
- + - - - -
- - - - + +
- + + + - +
- - - + - -
+ - + - + -
+ - - - - -
+ - - - - -
- - - - - -
Early Early Active Active Active Active
0 3 6 19 9 39
2 5 3 10 11 5
9 9 5 8 7 7
xide below 80% of predicted value; 3an erythrocyte sedimentation rate over
core; DLCO, diffusing capacity; ESR, erythrocyte sedimentation rate; NVC,
llaries; Cs, capillaries.
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and specificity values of different NEMO, GC and Cs
scores in correctly classifying active patients defined by
ESSG index cut-off values of both 3.5 and 3.0 were rep-
resented in Figure 2. Generally speaking, NEMO score
works better with respect to GC and Cs scores in identi-
fying patients with active disease, and the area under the
curve (AUC) of the NEMO score ROC plots were higher
than the corresponding AUC of either GC or Cs ROC
curves. Both differences reached the level of significance
(P <0.03 and P <0.0006, respectively, considering the two-
tailed Hanley-McNeil test) when the ESSG index cut-off
value of 3.5 was taken into account. Similarly the AUC of
the NEMO score was significantly higher than that of the
GC score and Cs score when the ESSG index cut-off value
of 3.0 was considered (P <0.05 and P <0.0001, respectively;
see Figure 2 for details).
A NEMO score ≥6, a GC score ≥3, and a Cs score ≤6
showed the most balanced performance in terms of sen-
sitivity/specificity ratio and the best accuracy in correctly
classifying patients with active disease at both cut-off
values considered (Table 3).
When the distribution of NEMO score according to
the NVC patterns was analysed, it appears evident that
the highest NEMO score values and majority of patients
with NEMO scores ≥6 were found in the population ofFigure 2 ROC curves obtained by plotting the sensitivity and 1-specif
patients (taking into account either a ESSG index ≥3.5 or ≥3). Cs ROC
specificity considering the maximum value observed as 1 (15, patient num
comparable to those obtained for the NEMO and GC ROC plot. When the
DA were evaluated (panel A), the area under the curve (AUC) defined for t
greater than that derived from both GC (AUC = 0.73, 95% CI 0.63 to 0.83) a
value ≥3 was considered as indicative of DA (panel B), the AUC of the NEM
than that derived from GC score (AUC 0.8, 95% CI 0.71 to 0.83) and Cs scor
confidence interval; Cs, capillaries; DA, disease activity; ESSG, European Scle
micro-haemorrhages; ROC, receiver operating characteristic.patients classified as having the ‘active’ NVC pattern
[15] (27/43, 62,8%). However, a relevant number of pa-
tients with a NEMO score ≥6 could also be found in the
‘early’ and ‘late’ SSc population [15]. Eight out of eleven
patients with the early and all of the five with the late
scleroderma pattern having a NEMO score ≥6 had an
ESSG index ≥3.5.
When a NEMO score ≥6, a GC score ≥3 and a Cs
score ≤6 were analysed all together as predictors of an
active phase of disease (ESSG score ≥3.0), by building a
logistic regression model, only NEMO and GC variables
gave a significant contribution to the model, although
the odds ratio of NEMO score was much higher with re-
spect to that of GC score (Table 4).
With this figure in mind, we tested sensitivity, specificity
and accuracy of a modified (m) NEMO score where a
classification of the patients as active was indicated by the
presence of ≥6 MHE/MT, or - alternatively - by the con-
temporary presence of <6 MHE/MT plus a variable num-
ber of GC. A mNEMO defined by the presence of ≥6
MHE/MT, or alternatively by the presence of three to five
MHE/MT plus at least three GC showed the best accuracy
(88.7%) in correctly classifying patients with either moder-
ate or high active disease (with an ESSG score ≥3), with a
sensitivity of 95.1% and a specificity of 84.8%., and an odds
ratio of 109.2 (95% CI 22.7 to 526.1, P <0.0001).icity values of NEMO, GC and Cs scores in classifying active
curve was plotted using sensitivity and the reciprocal values of
ber 37). This was done to obtain a plot over the reference line
ROC curves obtained considering a ESSG ≥3.5 as the cut-off value for
he NEMO score (AUC = 0.89, 95% CI 0.84 to 0.95) was significantly
nd Cs scores (AUC 0.64, 95% CI 0.51 to 0.73). When a ESSG cut-off
O ROC curve (AUC 0.91, 95% CI 0.84 to 0.96) was significantly higher
e (AUC 0.63, 95% CI 0.52 to 0.74). AUC, area under the curve; CI,
roderma Study Group; GC, giant capillaries; NEMO, number of
Table 3 Performance of NEMO, GC, and Cs scores in
classifying patients with different ESSG scores
NEMO score ≥6 for ESSG ≥3 NEMO score ≥6 for ESSG ≥3.5
Sensitivity 82.9 Sensitivity 87.5
Specificity 87.9 Specificity 81.3
Accuracy 86.0 Accuracy 83.2
GC score ≥3 for ESSG ≥3 GC score ≥3 for ESSG ≥3.5
Sensitivity 70.7 Sensitivity 65.6
Specificity 80.3 Specificity 72.0
Accuracy 76.6 Accuracy 70.0
Cs score ≤6 for ESSG ≥3 Cs score ≤6 for ESSG ≥3.5
Sensitivity 40 Sensitivity 40.6
Specificity 62.5 Specificity 70.6
Accuracy 54.6 Accuracy 61.1
NEMO, number of micro-haemorrhages; GC, giant capillaries; Cs, capillaries;
ESSG, European Scleroderma Study Group.
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In this study, we demonstrated that the presence of a
given number of MHE and MT is highly indicative of an
active phase of disease. Even the presence of a sufficient
number of GC, and a reduced number of Cs may sug-
gest the presence of DA, although the strength of correl-
ation is higher for the former NVC abnormalities. A
score where the presence of a defined number of MHE
plus MT, and of a given amount GC were combined -
derived by a logistic regression model - showed the best
predictive value in selecting patients with a current level
of moderate and high DA.
NVC is a simple technique largely adopted in clinical
assessment of patients with SSc and other connective
tissue diseases [24]. Different applications have been de-
scribed for NVC in SSc. First of all, NVC has an import-
ant diagnostic value in SSc, and a specific pattern has
been described as characteristic of the disorder, generic-
ally defined as belonging to the scleroderma spectrum
[17]. Moreover, the recent ACR-EULAR classification
criteria for SSc include NVC among the proposed diag-
nostic items [11]. A relevant prognostic value has also
been ascribed to NVC, and different NVC patterns have
been defined to be predictive for a worse outcomeTable 4 Multiple logistic regression model evaluating the
statistical contribution of given values of different NVC
scores as a predictor of DA (ESSG ≥3)
Variables Odds ratio 95% CI* P value
NEMO score ≥6 22.05 6.98-69.64 <0.0001
GC score ≥3 3.62 1.14-11.5 0.02
Cs score ≤6 2 0.57-7.5 0.26
*95% confidence interval. NVC, nailfold videocapillaroscopy; DA, disease
activity; ESSG, European Scleroderma Study Group; NEMO, number of
micro-haemorrhages; GC, giant capillaries; Cs, capillaries.[12-14], and for some specific complications of the dis-
orders [25,26]. Finally, NVC has also been used to sub-
classify patients with SSc according with the phases of
disease course, and different NVC patterns described for
early, active, and late disease [15]. Conversely, so far, no
studies have been carried out specifically aimed at evalu-
ating the potential utility of NVC in stratifying patients
according to the level of DA.
The fact that, according to our results, MHE and MT
are the NVC abnormalities more strictly indicative of a
current DA status is not completely surprising. SSc is
usually defined as a disease of the micro-vascular bed of
the skin compartment, but potentially compromising the
small vessels of internal organs. The endothelial involve-
ment is considered the ‘primum movens’ of the patho-
logical process in SSc, while migration of mononuclear
inflammatory cells in the interstitium, activation of myo-
fibroblast and fibroblast lineage, with the consequent
increased production of extracellular matrix and then fi-
brosis, could be considered as the following stages [2-4].
A large body of evidence indicates that the typical re-
sponse to the initial micro-vascular damage and capillary
loss in SSc is represented by the compensatory dilatation
of remaining capillary loops with formation of GC [17]. In
slowly evolving or stable disease, it is not unusual to ob-
serve GC unchanged over time. On the contrary, in pro-
gressive disorder, the destiny of enlarged capillaries is
thrombotic obliteration followed by extravasation. When
these phenomena are synchronous in many capillaries,
serial extravasations with hemosiderin deposits can be ob-
served in the NVC, aligned distally in the cuticle [16].
The finding that the presence of a given amount of
MHE and MT (more strongly than that of GC) is associ-
ated with DA phases in SSc seems to confirm that these
specific abnormalities could represent the NVC counter-
part of a rapidly evolution of micro-vascular involvement
in active disease phases. The fact that the correlation is
less strong for GC can be ascribed to the well-know find-
ing that some GC may appear stable over time in sequen-
tial NVC examinations, and then their presence cannot
reflect an active phase of the disease. Conversely, the re-
duction in the number of Cs may be regarded as the final
outcome of pathological process in the capillary bed, once
the capillary reconstruction attempts have failed. Of
course, in a longitudinal study, where a rapidly progressive
reduction of capillary number may be assessed in two
or more consecutive NVC examinations, one can cer-
tainly consider this finding as expression of an active
evolving phase of the disease. This is not the case of the
present cross-sectional study in which we demonstrated
that the current state of DA is more closely represented
by the presence of MH and MT. This statement is cer-
tainly reinforced by the observation that MHE and MT,
but not GC, have been described in other disorders
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is an important pathological aspect, although induced
by partially different mechanisms [27-30].
Since in a specific logistic model the presence of a cer-
tain number GC appear to be also predictive for DA, al-
though to a lesser extent, we checked whether a given
combination of all these NVC abnormalities could better
identify patients with a relevant DA. The modified score
(mNEMO score), in which both MHE/MT and GC were
included, demonstrated to be actually more accurate and
valid for this purpose.
We are, of course, aware that any instrument devoted to
assess DA should be not only valid and reliable but also
sensitive to change. Not a cross-sectional study like the
present one, but a longitudinal study, where the instru-
ment is used to assess changes of DA over time, is cer-
tainly needed to verify this latter characteristic.
The here proposed NVC scoring system named
mNEMO appears a feasible instrument to assess DA in
SSc, since it is possible to predict an active phase of dis-
ease during an outpatient visit and in a rather short time.
On the contrary, to evaluate the same entity with the pre-
viously proposed methods implies a complicate and time-
consuming patient work-up. Of course, patients in whom
this specific NVC approach may suggest an active phase
of disease should be addressed to a more careful clinical,
instrumental and serological evaluation to confirm the
suspicion and more precisely define the specific clinical
profile. Once a patient has been definitely classified as be-
ing in an active phase of disease, a more aggressive thera-
peutic strategy should be taken into consideration, in
accordance with the present recommendations that sug-
gest treating active patients as soon as possible, in order
to tentatively modify the natural course of SSc.
Conclusions
Some specific features observed during NVC examination,
such as MHE/MT and GC are strongly predictive of mod-
erate or high level of DA in SSc. A scoring system derived
by these findings has been developed and proposed.
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